New CPT® Codes Approved for COVID-19 Antibody Identification

April 15th, 2020 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
Categories:   CPT® Coding   Billing   Cardiology|Vascular   Emergency Medicine   ENT|Otolaryngology   Gastroenterology   Home Health|Hospice   Internal Medicine   Laboratory|Pathology   Oncology|Hematology   Pulmonology   Skilled Nursing   Reimbursement   Covid-19  
0 Votes - Sign in to vote or comment.

On April 10, 2020, the American Medical Association approved and published a revision of code 86318 and added two new codes 86328 and 86769 for reporting Coronavirus [COVID-19] antibody testing. The descriptions for these codes are as follows: 

86318  Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip);

86328        ; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(Coronavirus disease [COVID-19])

86769   Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(Coronavirus disease [COVID-19])

The revision changes 86318 to a parent code describing single-step antibody testing (e.g., reagent strip). It then lists beneath it 86328 to identify single-step antibody testing (e.g., reagent strip) specific to SARS-CoV-2 or the Coronavirus [COVID-19] antibodies. Code 86769 was added to report a multi-step, more in-depth test for the same antibodies. 

To clarify, antigens are the unique molecules of pathogens (e.g., bacteria, viruses). When a virus enters the body the immune system signals antibodies (a protein produced mostly by plasma cells) to attach themselves to the antigens and systematically destroy them. Immunoglobulin G (IgG) and immunoglobulin M (IgM) are two known antibodies that when present in testing provide information on what is occurring in the body. IgG is found in all bodily fluids and protects against infections while IgM is found mostly in lymphatic fluids and blood serum or plasma and is the first antibody made by the body to fight off a new infection. The presence of these antibodies helps identify a positive COVID-19 result. 

The two most recent codes the AMA approved for this type of testing include: 

86328, which uses a blood serum or plasma sample that is placed into a single well on a reagent strip with controls for IgG and IgM. The result is read optically (visually) and recorded in the patient’s medical record.

86769, which uses a blood serum or plasma sample that is placed into a multi-well plate that is incubated and washed. It then has IgG and IgM antibodies added, and is incubated again before finally being measured using a microtiter plate reader. The results of this test are measured and require interpretation and a separate report by a physician.

Antibody testing is not the only method used for identifying a patient infected with SARS-CoV-2. Another new code that was approved for reporting and became effective on March 13, 2020, is:

87635  Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

This type of testing includes reverse transcription quantitative polymerase chain reaction (RT-qPCR) or amplified probe technique. In order to perform the test, a sample from the nasopharyngeal or oropharyngeal area must be collected, which is done by inserting a long cotton swab into the area where the nose meets the throat (nasopharyngeal space) and swabbing the area to collect viral RNA cells for testing. This method, although noninvasive (not cutting into the body), is very uncomfortable for the patient. 

Due to the virus’ atypically long incubation period (the time from exposure to becoming symptomatic), nasopharyngeal swab testing hasn’t necessarily been the best testing method. Consequently, a number of “false negative” test results have occurred due to:

  • the timing of the test (start of the infection vs. onset of symptoms)
  • the sampling technique used (which varies from nurse to nurse), and 
  • whether or not enough viral RNA was collected for the test

While these testing methods (87635, 86328, 86769) are all different, sometimes a combination of them is required to ensure accurate test results. As with any new codes added during the year, they will not be included in the current (2020) CPT® codebook but will be in the 2021 edition. Please note that code 87635 was effective as of March 13, 2020, but revised code 86318 and new codes 86328 and 86769 are effective as of  April 10, 2020. 

The AMA has provided clinical examples for the use of these codes in their “CPT Assistant Special Edition” and “CPT Assistant Special Edition: April Update,” which are useful in ensuring proper code assignment. Also, don’t forget to assign the proper ICD-10-CM codes as well, which is discussed in the article “Understanding the New Codes for Testing & Reporting COVID-19 Coronavirus (SARS-CoV-2)” and “ICD-10-CM Official Coding and Reporting Guidelines UPdated for COVID-19.”

###

Questions, comments?

If you have questions or comments about this article please contact us.  Comments that provide additional related information may be added here by our Editors.


Latest articles:  (any category)

​​Polysomnography Services Under OIG Scrutiny
September 2nd, 2021 - Raquel Shumway
The OIG conducted a study dated June 2019 wherein they indicated that there were approximately $269 million in overpayments for polysomnography services for the period of 2014 through 2015. According to the OIG “These errors occurred because the CMS oversight of polysomnography services was insufficient to ensure that providers complied with Medicare requirements and to prevent payment of claims that didn’t meet those requirements.” So what are those requirements?
Medicare Advantage - The Fastest Growing Government-Funded Program Undergoing Multiple Fraud Investigations
August 16th, 2021 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
Medicare Advantage is the fastest growing form of government-funded healthcare and the rate of fraud within this segment has come under increased scrutiny. Funding is determined by the health status of each beneficiary; therefore, accurate coding based on detailed documentation makes the medical record vital to the process because some ...
Billing Dental Implants under Medical Coverage
August 12th, 2021 - Christine Woolstenhulme, QCC, QMCS, CPC, CMRS
Implants can be costly to the patient and the provider, and it is crucial to understand how to bill a patient’s medical insurance to ensure there is adequate coverage for the best treatment. Implants are commonly billed in a dental office under a patient’s medical benefits.    Implants could be considered ...
New Codes for COVID Booster Vaccine & Monoclonal Antibody Products
August 10th, 2021 - Wyn Staheli, Director of Research
New codes have been announced for the COVID-19 booster vaccine, Novavax vaccine, and monoclonal antibody treatment.
Medicare's ABN Booklet Revised
July 29th, 2021 - Wyn Staheli, Director of Research
The “Medicare Advance Written Notices of Non-coverage” booklet, published by CMS’s Medicare Learning Network, was updated. This article discusses the changes to this booklet regarding the use of the ABN.
Chronic Pain Coding Today & in the Future
July 19th, 2021 - Wyn Staheli, Director of Research
Properly documenting and coding chronic pain can be challenging. As is commonly the case with many conditions, over the years, there has been a shift in the identification of different types of pain, including chronic pain. Understanding where we are now and where we are going will help your organization prepare for the future by changing documentation patterns now.
How Does Global and Professional Direct Contracting (GPDC) Affect Risk Adjustment?
July 15th, 2021 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
CMS recently announced the 53 Direct Contracting Entities (DCEs) that will be participating in the April 1, 2021 through December 31, 2021 Global and Professional Direct Contracting (GPDC) Model. Among those participating is Clover Health Partners, who runs an in-home primary care program that has the potential to help Medicare ...



Home About Contact Terms Privacy

innoviHealth® - 62 E 300 North, Spanish Fork, UT 84660 - Phone 801-770-4203 (9-5 Mountain)

Copyright © 2000-2021 innoviHealth Systems®, Inc. - CPT® copyright American Medical Association